Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs - Wildemberg, L E; Neto, L V; Costa, D F (J Endocrinol Invest, 2013)
et al.